Supply Chain Intelligence

Kiniksa Pharmaceuticals International, plc Supply Chain

KNSA supply chain intelligence for Kiniksa Pharmaceuticals International, plc: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

KNSA ·Last updated 2026-10-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
12Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

Kiniksa Pharmaceuticals International, plc (KNSA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

20Total relationships
3Distinct source URLs
9High confidence
0.771Average confidence
2026-10-29Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Kiniksa Pharmaceuticals International, plc Suppliers

TickerNameConfidenceEvidence
GENENTECH GENENTECH 92% Pursuant and subject to the terms of the Genentech License Agreement, Genentech has the exclusive worldwide right to conduct development and commercialization activities for Genentech Licensed Produc…
REGENERON REGENERON 90% Pursuant to the Regeneron Agreement, we have an exclusive right to develop and commercialize certain products under the Regeneron Agreement.
SAMSUNG SAMSUNG 90% we have entered into a Master Services Agreement and a Product Specific Agreement with Samsung.
CDMO CDMO 85% we have additionally entered into agreements with several CDMOs to provide us with preclinical and clinical trial materials for our non-ARCALYST assets
REGN Regeneron Pharmaceuticals, Inc. 72% Reciprocal relationship from REGN graph: Reciprocal relationship from KNSA graph: Reciprocal relationship from REGN graph: Reciprocal relationship from KNSA graph: Reciprocal relationship from REGN g…

Kiniksa Pharmaceuticals International, plc Customers

TickerNameConfidenceEvidence
THIRD-PARTY-LOGISTICS-PROVIDER THIRD-PARTY-LOGISTICS-PROVIDER 92% ARCALYST is sold through a third-party logistics provider that distributes primarily through a select network of specialty pharmacies (collectively, "customers"), which deliver the medication to pati…
HUADONG HUADONG 90% In February 2022 we entered into two collaboration and license agreements (each, a "Huadong Collaboration Agreement" and together, the "Huadong Collaboration Agreements") with Huadong, pursuant to wh…
AZN AstraZeneca PLC 72% velop and commercialize ARCALYST worldwide, excluding the Middle East and North Africa, for all indications other than those in oncology and local administration to the eye or ear. Upon receiving pos…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from KNSA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from KNSA graph: Reciprocal relationship from AZN grap…
REGN Regeneron Pharmaceuticals, Inc. 72% en they are labeled as free goods. ​ The Company is conducting a technology transfer of ARCALYST drug substance manufacturing from Regeneron Pharmaceuticals, Inc. (“Regeneron”) to Samsung Biologics C…
REGN Regeneron Pharmaceuticals, Inc. 72% Reciprocal relationship from REGN graph: Reciprocal relationship from KNSA graph: Reciprocal relationship from REGN graph: Reciprocal relationship from KNSA graph: en they are labeled as free goods. …
BIOGEN-MA-INC BIOGEN-MA-INC 62% ,083 ) ​ $ ( 7,656 ) ​ $ 261 Huadong ARCALYST ​ ​ 12,000 ​ ​ — ​ ​ — ​ ​ — ​ ​ 12,000 Total Contract Liabilities ​ $ 12,000 ​ $ 45,000 ​ $ ( 37,083 ) ​ $ ( 7,656 ) ​ $ 12,261 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 13…
HANGZHOU-ZHONGMEI-HUADONG-PHARMACEUTICAL-CO-LTD HANGZHOU-ZHONGMEI-HUADONG-PHARMACEUTICAL-CO-LTD 62% KINIKSA PHARMACEUTICALS, LTD. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Amounts in thousands, except share and per share amounts) ​ obligation in the Genentech License Agreement was det…
MEDIMMUNE-LIMITED MEDIMMUNE-LIMITED 62% velop and commercialize ARCALYST worldwide, excluding the Middle East and North Africa, for all indications other than those in oncology and local administration to the eye or ear. Upon receiving pos…
PRIMATOPE-THERAPEUTICS-INC PRIMATOPE-THERAPEUTICS-INC 62% y classified. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical and clinical development, process development and manufactur…
SAMSUNG-BIOLOGICS-CO-LTD SAMSUNG-BIOLOGICS-CO-LTD 62% en they are labeled as free goods. ​ The Company is conducting a technology transfer of ARCALYST drug substance manufacturing from Regeneron Pharmaceuticals, Inc. (“Regeneron”) to Samsung Biologics C…
UK-LTD UK-LTD 62% uch, are not separately classified. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical and clinical development, process deve…

Kiniksa Pharmaceuticals International, plc Debt Obligations

InstrumentDescriptionConfidenceEvidence
KNSA-DEBT-10541 Xbrl Convertible 90% xbrl convertible detail from xbrl 2018-12-31.
KNSA-DEBT Debt stack $9.0M 90% Market cache reports total debt of $9.0M.

Kiniksa Pharmaceuticals International, plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Kiniksa Pharmaceuticals International, plc.

Kiniksa Pharmaceuticals International, plc Ownership

HolderNameConfidenceEvidence
KNSA-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 230 tracked holders.

Kiniksa Pharmaceuticals International, plc Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
DRTS Alpha Tau Medical Ltd. 100.00 2
TBPH Theravance Biopharma, Inc. 100.00 2
ACET Adicet Bio, Inc. 100.00 2
ARTV Artiva Biotherapeutics, Inc. 100.00 2
IDYA IDEAYA Biosciences, Inc. 100.00 2
KLRS Kalaris Therapeutics, Inc. 100.00 2
DEO Diageo plc 100.00 2
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 1 ['customer', 'supplier']
AZN AstraZeneca PLC 100.00 1 ['customer']
EDSA Edesa Biotech, Inc. 100.00 2
BCAX Bicara Therapeutics Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
OLMA Olema Pharmaceuticals, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Kiniksa Pharmaceuticals International, plc.

Unlock full KNSA data, View plans →
ChainSifter · Guerilla Finance support@chainsifter.com Terms Disclaimer ← Back to Map
🔐
KNSA
Unlock KNSA Supply Chain Data
Verified relationships include:
GENENTECHGENENTECHSupplier92%
REGENERONREGENERONSupplier90%
THIRD-PARTY-LOGISTICS-PROVIDERTHIRD-PARTY-LOGISTICS-PROVIDERCustomer92%
HUADONGHUADONGCustomer90%
+16 more relationships locked
Subscribe, View plans →
Already a subscriber? Sign in →